Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

414 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12.
Armuzzi A, Rubin DT, Schreiber S, Panés J, Fellmann M, Bartolome L, Gruben D, Goetsch M, Bhattacharjee A, Chaparro M, Dubinsky MC. Armuzzi A, et al. Among authors: chaparro m. Inflamm Bowel Dis. 2024 Sep 26:izae229. doi: 10.1093/ibd/izae229. Online ahead of print. Inflamm Bowel Dis. 2024. PMID: 39326009
Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients.
Chaparro M, Ordás I, Cabré E, Garcia-Sanchez V, Bastida G, Peñalva M, Gomollón F, García-Planella E, Merino O, Gutiérrez A, Esteve M, Márquez L, Garcia-Sepulcre M, Hinojosa J, Vera I, Muñoz F, Mendoza JL, Cabriada JL, Montoro MA, Barreiro-de Acosta M, Ceña G, Saro C, Aldeguer X, Barrio J, Maté J, Gisbert JP. Chaparro M, et al. Inflamm Bowel Dis. 2013 Jun;19(7):1404-10. doi: 10.1097/MIB.0b013e318281f28f. Inflamm Bowel Dis. 2013. PMID: 23665964
The effects of infliximab or adalimumab on vascular endothelial growth factor and angiopoietin 1 angiogenic factor levels in inflammatory bowel disease: serial observations in 37 patients.
Algaba A, Linares PM, Encarnación Fernández-Contreras M, Figuerola A, Calvet X, Guerra I, de Pousa I, Chaparro M, Gisbert JP, Bermejo F. Algaba A, et al. Among authors: chaparro m. Inflamm Bowel Dis. 2014 Apr;20(4):695-702. doi: 10.1097/MIB.0000000000000004. Inflamm Bowel Dis. 2014. PMID: 24562175
A genome-wide association study identifies a novel locus at 6q22.1 associated with ulcerative colitis.
Julià A, Domènech E, Chaparro M, García-Sánchez V, Gomollón F, Panés J, Mañosa M, Barreiro-De Acosta M, Gutiérrez A, Garcia-Planella E, Aguas M, Muñoz F, Esteve M, Mendoza JL, Vera M, Márquez L, Tortosa R, López-Lasanta M, Alonso A, Gelpí JL, García-Montero AC, Bertranpetit J, Absher D, Myers RM, Gisbert JP, Marsal S. Julià A, et al. Among authors: chaparro m. Hum Mol Genet. 2014 Dec 20;23(25):6927-34. doi: 10.1093/hmg/ddu398. Epub 2014 Jul 31. Hum Mol Genet. 2014. PMID: 25082827
Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort.
Khorrami S, Ginard D, Marín-Jiménez I, Chaparro M, Sierra M, Aguas M, Sicilia B, García-Sánchez V, Suarez C, Villoria A, Taxonera C, Velasco-Guardado A, Martínez-González J, Gisbert JP. Khorrami S, et al. Among authors: chaparro m. Inflamm Bowel Dis. 2016 Jul;22(7):1662-9. doi: 10.1097/MIB.0000000000000842. Inflamm Bowel Dis. 2016. PMID: 27306072 Free article.
Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective Study.
Kopylov U, Papamichael K, Katsanos K, Waterman M, Bar-Gil Shitrit A, Boysen T, Portela F, Peixoto A, Szilagyi A, Silva M, Maconi G, Har-Noy O, Bossuyt P, Mantzaris G, Barreiro de Acosta M, Chaparro M, Christodoulou DK, Eliakim R, Rahier JF, Magro F, Drobne D, Ferrante M, Sonnenberg E, Siegmund B, Muls V, Thurm T, Yanai H, Dotan I, Raine T, Levin A, Israeli E, Ghalim F, Carbonnel F, Vermeire S, Ben-Horin S, Roblin X. Kopylov U, et al. Among authors: chaparro m. Inflamm Bowel Dis. 2017 Sep;23(9):1605-1613. doi: 10.1097/MIB.0000000000001160. Inflamm Bowel Dis. 2017. PMID: 28590343
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry.
Casanova MJ, Chaparro M, Mínguez M, Ricart E, Taxonera C, García-López S, Guardiola J, López-San Román A, Iglesias E, Beltrán B, Sicilia B, Vera MI, Hinojosa J, Riestra S, Domènech E, Calvet X, Pérez-Calle JL, Martín-Arranz MD, Aldeguer X, Rivero M, Monfort D, Barrio J, Esteve M, Márquez L, Lorente R, García-Planella E, de Castro L, Bermejo F, Merino O, Rodríguez-Pérez A, Martínez-Montiel P, Van Domselaar M, Alcaín G, Domínguez-Cajal M, Muñoz C, Gomollón F, Fernández-Salazar L, García-Sepulcre MF, Rodríguez-Lago I, Gutiérrez A, Argüelles-Arias F, Rodriguez C, Rodríguez GE, Bujanda L, Llaó J, Varela P, Ramos L, Huguet JM, Almela P, Romero P, Navarro-Llavat M, Abad Á, Ramírez-de la Piscina P, Lucendo AJ, Sesé E, Madrigal RE, Charro M, García-Herola A, Pajares R, Khorrami S, Gisbert JP. Casanova MJ, et al. Among authors: chaparro m. Inflamm Bowel Dis. 2020 Mar 4;26(4):606-616. doi: 10.1093/ibd/izz192. Inflamm Bowel Dis. 2020. PMID: 31504569 Free article.
414 results